Dr. Andrew R. Greenspan

Oncology
6845 Rama Dr, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
6845 Rama Dr, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Greenspan is an Oncologist in Indianapolis, Indiana. Dr. Greenspan is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Paget Disease of the Breast, and Colorectal Cancer. Dr. Greenspan is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Iu Health West Hospital
Indiana University Health North Hospital
Indiana University Health Arnett Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

INDIANA UNIVERSITY HEALTH INC
6845 Rama Dr, Indianapolis, IN 46219
Other Locations
IU HEALTH MEDICAL GROUP LLC
1701 N Senate Blvd, Indianapolis, IN 46202
INDIANA UNIVERSITY HEALTH INC
1030 W Michigan St, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 2
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: May 23, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Nab-paclitaxel, MK-3475
Study Phase: Phase 1/Phase 2
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Advanced in Myelofibrosis
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology
Advanced in Myelofibrosis
Dr. Seyed H. Sayar
Hematology Oncology | Oncology | Hematology

Indiana University Health Care Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (7.1 miles away)
317-944-4897
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Seyed Sayar is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Sayar is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Sayar is currently accepting new patients.

Advanced in Myelofibrosis
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine
Advanced in Myelofibrosis
Dr. Larry D. Cripe
Hematology Oncology | Hematology | Palliative Medicine

Iu Health Medical Group LLC

1701 N Senate Ave, 
Indianapolis, IN 
 (6.1 miles away)
317-962-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Cripe is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Cripe is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Childhood Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Cripe is currently accepting new patients.

Advanced in Myelofibrosis
Dr. Jennifer E. Schwartz
Hematology | Hematology Oncology | Oncology
Advanced in Myelofibrosis
Dr. Jennifer E. Schwartz
Hematology | Hematology Oncology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (6.2 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Schwartz is a Hematologist and a Hematologist Oncology provider in Indianapolis, Indiana. Dr. Schwartz is rated as an Advanced provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant. Dr. Schwartz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenspan's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 64 Advanced Conditions
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile